Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Patient Support Specialist Job
Celgene Corporation - Berkeley Heights, NJ, US
Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY
Clinical Trials Site Director
Lovelace Respiratory Research Institute - Albuquerque, NM
Manager, Strategic Forecasting & Analytics Job
Celgene Corporation - Basking Ridge, NJ, US
Principal Scientist
Watson Pharmaceuticals - Fort Lauderdale, FL

More Jobs >>

Events

Enforcement, Litigation and Compliance Conference
Dec. 6-7 — Washington, DC
Life Science in the Cloud
Nov 16, 2011 — Cambridge, MA
Just Released: New Trends in Preventive and Therapeutic Vaccine
Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston

More Events >>

Related Tags >> GlycoVaxyn Novartis universal flu vaccine

biotech venture capital News

Most Popular biotech venture capital Story

Novartis VC arm backs fledgling universal flu vax

February 17, 2010 — 4:29pm ET | By John Carroll

The venture arm of Novartis has joined a group of investors channeling $13.6 million in fresh funds for Immune Targeting Systems, which is hard at work on an experimental universal flu vaccine. ITS Read more...

biotech venture capital Press Releases

Venture Capital Investments Decline in Dollars and Deal Volume in Q3 2011
Investment in U.S. Venture Companies Rose 35% in First Quarter
Venture Capital Investment Dollars Increase Modestly While Number of Deals Declines in Q1 2011
ANNUAL VENTURE INVESTMENT INCREASES FOR FIRST TIME SINCE 2007, ACCORDING TO THE MONEYTREE REPORT
Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing

Latest Headlines

Novartis VC arm backs fledgling universal flu vax
February 17, 2010
GlycoVaxyn banks $22 million in second round
March 5, 2009

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK